标题
Current status and future perspectives in HER2 positive advanced gastric cancer
作者
关键词
-
出版物
Clinical & Translational Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-01
DOI
10.1007/s12094-021-02760-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer
- (2020) TAKASHI KIJIMA et al. ANTICANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
- (2020) Juliette Palle et al. DRUGS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
- (2019) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
- (2019) Lorenzo Fornaro et al. BRITISH JOURNAL OF CANCER
- A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
- (2019) Tae-Yong Kim et al. Gastric Cancer
- Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
- (2019) Daisuke Takahari et al. Gastric Cancer
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
- (2019) Taroh Satoh et al. Gastric Cancer
- [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
- (2019) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
- (2019) Claudio Vernieri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
- (2019) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- (2019) Kohei Shitara et al. LANCET ONCOLOGY
- Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
- (2019) Steven B. Maron et al. CLINICAL CANCER RESEARCH
- Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
- (2019) Le-Tian Huang et al. Frontiers in Oncology
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
- (2018) Aziz Zaanan et al. DIGESTIVE AND LIVER DISEASE
- HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer
- (2018) Haixing Wang et al. EUROPEAN JOURNAL OF CANCER
- Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection
- (2018) Sumbal Sumbal et al. EXPERIMENTAL HEMATOLOGY
- Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis
- (2018) Emil ter Veer et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
- (2018) Jiaolong Shi et al. ONCOGENE
- ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
- (2018) Martin H.D. Neumann et al. Computational and Structural Biotechnology Journal
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
- (2018) Yosuke Horita et al. ANTI-CANCER DRUGS
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
- (2018) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
- (2018) Ronan Joseph Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
- (2018) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
- (2018) Valentina Gambardella et al. CLINICAL CANCER RESEARCH
- Immunotherapy in advanced gastric cancer, is it the future?
- (2018) C. Coutzac et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
- (2018) Markus Moehler et al. Future Oncology
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- ZW25 Effective in HER2-Positive Cancers
- (2018) Cancer Discovery
- Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
- (2017) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- (2017) Joseph A. O'Donoghue et al. JOURNAL OF NUCLEAR MEDICINE
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
- (2017) Yuji Mishima et al. Targeted Oncology
- Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer
- (2017) Minghua Sui et al. Experimental and Therapeutic Medicine
- Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer
- (2017) Yukiya Narita et al. Oncology Letters
- PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
- (2017) Chan Kim et al. Oncotarget
- Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
- (2017) Juliette Palle et al. Oncotarget
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
- (2016) Jifang Gong et al. BMC CANCER
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
- (2016) G. Piro et al. CLINICAL CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma
- (2016) Yasunori Deguchi et al. Gastric Cancer
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer
- (2016) Eric Van Cutsem et al. LANCET
- Involvement of microRNAs in HER2 signaling and trastuzumab treatment
- (2016) Ling Mao et al. TUMOR BIOLOGY
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
- (2016) C. Alix-Panabieres et al. Cancer Discovery
- Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
- (2016) Qian Li et al. Oncotarget
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
- (2016) Chiara Arienti et al. Oncotarget
- Novel targets in the treatment of advanced gastric cancer: a perspective review
- (2016) Elisa Fontana et al. Therapeutic Advances in Medical Oncology
- Droplet digital PCR measurement of HER2 in patients with gastric cancer
- (2015) H Kinugasa et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience
- (2015) Roberto Petrioli et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
- (2015) Do-Youn Oh et al. Gastric Cancer
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer
- (2015) Naoki Takahashi et al. Oncotarget
- Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion
- (2015) Bharat K. R. Chaganty et al. OncoImmunology
- Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
- (2015) Ronan J Kelly et al. Journal for ImmunoTherapy of Cancer
- Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
- (2014) Zhi Peng et al. Biomarkers in Medicine
- Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
- (2014) Y Kurokawa et al. BRITISH JOURNAL OF CANCER
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study
- (2014) Katsutoshi Shoda et al. Gastric Cancer
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Circulating Tumor Cells (CTCs) Detected by RT-PCR and Its Prognostic Role in Gastric Cancer: A Meta-Analysis of Published Literature
- (2014) Shuyi Wang et al. PLoS One
- Extension lymphatique du cancer du poumon : une anatomie enchaînée dans des zones
- (2014) M. Riquet et al. Revue de Pneumologie Clinique
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Liquid biopsy of gastric cancer patients: Circulating tumor cells and cell-free nucleic acids
- (2014) Masahiro Tsujiura WORLD JOURNAL OF GASTROENTEROLOGY
- Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications
- (2014) Ju-Yu Tseng et al. Cancers
- HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
- (2013) Nadia Harbeck et al. Breast Care
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- (2013) Y. Y. Janjigian et al. JOURNAL OF NUCLEAR MEDICINE
- Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
- (2013) H-P Kim et al. ONCOGENE
- Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer
- (2013) Hakan Akca et al. Cancer Genetics
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
- (2012) G Minuti et al. BRITISH JOURNAL OF CANCER
- Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
- (2012) I Witzel et al. BRITISH JOURNAL OF CANCER
- Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth
- (2012) Deniz A. Ucar et al. CELL CYCLE
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
- (2012) Jan Trøst Jørgensen et al. Journal of Cancer
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
- (2011) C Bozzetti et al. BRITISH JOURNAL OF CANCER
- Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy
- (2011) Allan Lipton et al. CANCER
- B7-H3 expression in gastric cancer: A novel molecular blood marker for detecting circulating tumor cells
- (2011) Takaaki Arigami et al. CANCER SCIENCE
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical appraisal of trastuzumab in treatment of advanced stomach cancer
- (2011) Judith Meza-Junco et al. Cancer Management and Research
- Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
- (2010) Adam Brufsky AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Circulating cancer cells
- (2010) D. Mavroudis ANNALS OF ONCOLOGY
- Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing
- (2010) Z. J. Zang et al. CANCER RESEARCH
- Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
- (2010) Norma O’Donovan et al. INVESTIGATIONAL NEW DRUGS
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now